Who
Frank Yocca
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, BioXcel Therapeutics.
In numbers
- Trades disclosed
- 106
- Buys
- 5
- Sells
- 11
- Bought
- $66K
- Sold
- $3.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Mar 2018
- Last trade
- 15 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —35 | filing |
| 15 Jun 2026filed 17 Jun 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —35 | filing |
| 20 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,4276,845 at $1.09 | filing |
| 20 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,4616,845 at $1.09 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —17,500 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —17,500 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —9,000 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,000 at $0.00 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,000 at $0.00 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —9,000 | filing |
| 15 Mar 2026filed 16 Mar 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —35 | filing |
| 15 Mar 2026filed 16 Mar 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35 at $0.00 | filing |
| 15 Mar 2026filed 16 Mar 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35 at $0.00 | filing |
| 15 Mar 2026filed 16 Mar 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —35 | filing |
| 14 Mar 2026filed 16 Mar 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —33 | filing |
| 14 Mar 2026filed 16 Mar 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.